Literature DB >> 14996671

Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel.

Satyanarayana R Pondugula1, Joel D Sanneman, Philine Wangemann, Pierre G Milhaud, Daniel C Marcus.   

Abstract

The semicircular canal duct (SCCD) epithelium is a vestibular epithelial domain that was recently shown to actively contribute to endolymph homeostasis by Cl(-) secretion under control of beta(2)-adrenergic stimulation. By analogy to other Cl(-) secretory epithelia, we hypothesized that SCCD also provides an active absorptive pathway for Na(+) under corticosteroid control. Measurements of short-circuit current (I(sc)) demonstrated stimulation (7-24 h) by the glucocorticoids hydrocortisone (EC(50) 13 nM), corticosterone (33 nM), prednisolone (70 nM), and dexamethasone (13 nM) over physiologically and therapeutically relevant concentrations and its block by amiloride (IC(50) 470 nM) and benzamil (57 nM), inhibitors of the epithelial sodium channel (ENaC). I(sc) was also partially inhibited by basolateral ouabain and Ba(2+), indicating the participation of Na(+)-K(+)-ATPase and a K(+) channel in Na(+) transport. By contrast, aldosterone stimulated I(sc) only at unphysiologically high concentrations (EC(50) 102 nM). The action of all steroids was blocked by mifepristone (RU-486; K(d) approximately 0.3 nM) but not by spironolactone (K(d) approximately 0.7 microM). Expression of mRNA for the alpha-, beta-, and gamma-subunits of ENaC was demonstrated in the presence and absence of glucocorticoids. These findings are the first to identify SCCD in the vestibular labyrinth as a site of physiologically significant ENaC-mediated Na(+) absorption and osmotically coupled water flux. They further demonstrate regulation of Na(+) transport by natural and therapeutic glucocorticoids. The results provide for the first time an understanding of the therapeutic benefit of glucocorticoids in the treatment of Meniere's disease, a condition that is associated with increased luminal fluid volume.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996671     DOI: 10.1152/ajprenal.00387.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  24 in total

Review 1.  ENaCs and ASICs as therapeutic targets.

Authors:  Yawar J Qadri; Arun K Rooj; Catherine M Fuller
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

Review 2.  Regulation of sodium transport in the inner ear.

Authors:  Sung Huhn Kim; Daniel C Marcus
Journal:  Hear Res       Date:  2011-05-18       Impact factor: 3.208

3.  Treatment of Menière's Disease.

Authors:  Jeffrey D Sharon; Carolina Trevino; Michael C Schubert; John P Carey
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

4.  Intratympanic dexamethasone injections for refractory Meniere' s disease.

Authors:  Hongmiao Ren; Tuanfang Yin; Yongde Lu; Weijia Kong; Jihao Ren
Journal:  Int J Clin Exp Med       Date:  2015-04-15

5.  Endolymphatic sodium homeostasis by extramacular epithelium of the saccule.

Authors:  Sung Huhn Kim; Daniel C Marcus
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

6.  Regulation of ENaC-mediated sodium transport by glucocorticoids in Reissner's membrane epithelium.

Authors:  Sung Huhn Kim; Kyunghee X Kim; Nithya N Raveendran; Tao Wu; Satyanarayana R Pondugula; Daniel C Marcus
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-14       Impact factor: 4.249

7.  Ion transport regulation by P2Y receptors, protein kinase C and phosphatidylinositol 3-kinase within the semicircular canal duct epithelium.

Authors:  Satyanarayana R Pondugula; Nithya N Raveendran; Daniel C Marcus
Journal:  BMC Res Notes       Date:  2010-04-14

8.  Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway.

Authors:  Hung Caohuy; Catherine Jozwik; Harvey B Pollard
Journal:  J Biol Chem       Date:  2009-07-17       Impact factor: 5.157

9.  Perilymph pharmacokinetics of markers and dexamethasone applied and sampled at the lateral semi-circular canal.

Authors:  Alec N Salt; Jared J Hartsock; Ruth M Gill; Fabrice Piu; Stefan K Plontke
Journal:  J Assoc Res Otolaryngol       Date:  2012-09-12

10.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.